Abbott Laboratories (ABT) Earnings Analysis

Abbott Laboratories (ABT) next reports earnings on 2026-10-21, consensus EPS 1.42 USD. Last quarter (2026-07-16) it beat with EPS 1.31 USD vs 1.28 USD est (+2.3%). It has beaten estimates in 8/8 recent quarters (100%). Trailing P/E 32.34.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does ABT next report earnings?

Next earnings date2026-10-21
Consensus EPS estimate1.42 USD
Revenue estimate13.01B

ABT earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-07-161.31 USD1.28 USD+2.3%Beat
2026-04-161.15 USD1.14 USD+0.9%Beat
2026-01-221.5 USD1.5 USD0%Beat
2025-10-151.3 USD1.3 USD0%Beat
2025-07-171.26 USD1.26 USD0%Beat
2025-04-161.09 USD1.07 USD+1.9%Beat
2025-01-221.34 USD1.34 USD0%Beat
2024-10-161.21 USD1.2 USD+0.8%Beat

Beat rate: 8/8 (100%) over reported quarters with consensus data.

ABT valuation and analyst view

Trailing P/E32.34
Trailing EPS3.112 USD
Price / book3.37
Dividend yield2.47%
Market cap175.30B
Analyst consensusBuy (31 buy / 10 hold / 0 sell)
Avg price target121 USD

Related research pages

Frequently asked questions

When is Abbott Laboratories (ABT)'s next earnings date?

Abbott Laboratories is next scheduled to report on 2026-10-21, with a consensus EPS estimate of 1.42 USD and revenue estimate of 13.01B.

Did ABT beat earnings last quarter?

In its 2026-07-16 report, ABT posted EPS of 1.31 USD versus a 1.28 USD estimate — a beat of 2.3%.

What is ABT's earnings track record?

Over the last 8 reported quarters with consensus data, ABT beat estimates 8 times (100%).

What is ABT's current P/E ratio and EPS?

ABT trades at a trailing P/E of 32.34 on trailing EPS of 3.112360517483721 USD.

What do analysts rate ABT?

Analyst consensus is "Buy" across 41 ratings (0 strong buy, 31 buy, 10 hold, 0 sell, 0 strong sell). Average 12-month price target: 121 USD.